SCHEMBL5778513

SCHEMBL5778513

CCSc1cccc(Oc2ncc(F)cc2C(=O)NC(O)C2CCCCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.43
PDE4B Q07343 15/20 0.41
PDE4A P27815 1/20 0.41
PDE4D Q08499 1/20 0.41
PTGER2 P43116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8312606 0.88 PDE4B (0.51) PDE4BPDE4APDE4D
SCHEMBL5840163 0.82 CNR1 (0.44) PDE4BPDE4APDE4D
SCHEMBL5839215 0.82 CNR1 (0.44) PDE4BPDE4APDE4D
SCHEMBL5839698 0.79 PDE4B (0.50) PDE4BPDE4APDE4D
SCHEMBL5839702 0.79 PDE4B (0.50) PDE4BPDE4APDE4D
SCHEMBL5778510 0.79 P2RX7 (0.46) PTGER4
SCHEMBL5749019 0.79 PTGER4 (0.44) PTGER4PDE4BPDE4APDE4DPTGER2
SCHEMBL5779293 0.78 PDE4B (0.49) PDE4BPDE4APDE4D
SCHEMBL5779289 0.78 PDE4B (0.49) PDE4BPDE4APDE4D
SCHEMBL5839350 0.78 PDE4B (0.49) PDE4BPDE4APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141586-B2 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. (US) 2006-11-28 US disclosed
EP-1651609-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS Pfizer Limited (GB) 2006-05-03 EP disclosed
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. 2005-02-10 US disclosed
WO-2005009966-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors CBR3, CBR1, PDE9A PTGER4 116/4885PDE4B 8/4885PDE4A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.